Abstract
There is little doubt that dementia of the Alzheimer type (DAT) is a multifactorial disease. The existence of a major gene for DAT is equivocal, however, a genetic predisposition is considered to be likely from the high concordance of DAT in monozygotic and dizygotic twins (1), and an increased frequency of the disease in relatives of affected patients (2). The long arm of chromosome 21 is the locus of predisposition (3). The expression of a number of genes encoding for various neuronal and non-neuronal proteins is also changed in DAT brains (4).
Keywords
- Alzheimer Disease
- Hepatic Encephalopathy
- Glutamine Synthetase
- Quinolinic Acid
- Glutamine Synthetase Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
“All this has been said before, but since nobody listened, it must be said again.”
André Gide
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jarvik, L F, Ruth, V. and Matsuyama, S.S. 1980, Organic brain syndrome and aging. A 6 year follow-up of surviving twins. Arch. Gen. Psychiatry 37: 280–286.
Heston, L.L. and White, J. 1980, A family study of Alzheimer disease and senile dementia; an interim report. In Psychopathology in the Aged (Cole, J.O and Barrett, J.E. Eds.) Raven Press, New York, pp 63–72
St. George-Hyslop, P.H., Tanzi, R.E., Polinski, R.J., Haines, J.L., Nee, L., Watkins, P.C., Myers, R.H., Feldman, R.G., Pollen, D., Drachman, D., Growdon, J., Bruni, A., Foncin, J.F., Salmon, D., Frommet, P., Amaducci, L., Sorbi, S., Piacentini, S., Stewart, G.D., Hobbs, W.J., Coneally, P.M. and Gusella, J.F. 1987, The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 235: 885–890.
Boyes, B.E., Walker, D.G., McGeer, P.L., and McGeer, E.G. 1992, Identification and characterization of a large human brain gene whose expression is increased in Alzheimer disease. Mol. Brain Res. 12: 47–57.
Selkoe, D.J. 1991, The molecular pathology of Alzheimer’s disease. Neuron 6: 487–498.
Delaere, P., Duyckaerts, C., Brion, J.T., Poulain, V. and Hauw, J.J. 1989, Tau, paired helical filaments and amyloid in the neocortex: A morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol. 77: 645–653.
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., De Theresa, R., Hill, R., Hausen, L.A. and Katzman, R. 1991, Physical basis of cognitive alterations in Alzheimer’s disease: synaptic loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572–580.
Lassmann, H., Fischer, P. and Jellinger, K. 1993, Synaptic pathology of Alzheimer’s disease. In Amyloid Precursor Proteins, Signal Transduction and Neural Transplantation. Proc. 7th Meeting of the Intern. Study Group on the Pharmacology of Memory Disorders Associated with Aging, pp 41–47.
Henderson, A.S. 1988, The risk factors of Alzheimer’s disease: a review and an hypothesis. Acta Psychiatr. Scand. 78: 257–275.
Alafiizoff, I., Adolfsson, R., Grundke-Iqbal, I. and Winblad, B. 1987, Blood-brain barrier in Alzheimer’s dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol. 73: 160–166.
Miklossy, J. 1993, Alzheimer’s disease, a spirochetosis? Neuro Report 4: 841–848.
Harman, D. 1984, Free radical theory of aging: The “free radical” diseases. Age 7: 111–131.
Jeandel, C., Nicolas, M.B., Dubois, F., Nabet-Belleville, F., Penin, F. and Cuny, G. 1989, Lipid peroxidation and free-radical scavengers in Alzheimer’s disease. Gerontology 35: 275–282.
Volicer, L. and Crino, P.B. 1990, Involvement of free radicals in dementia of the Alzheimer type: an hypothesis. Neurobiol. Aging 11: 567–571.
Crowther, R.A. 1993, Tau protein and paired helical filaments of Alzheimer’s disease. Current Opinion Struct. Biol. 3: 202–206.
Fowler, C.J., Cowburn, R.F. and O’Neill, C. 1992, Brain signal transduction distrubances in neurodegenerative disorders. Cell. Signal. 4: 1–9.
Christensen, H., Maltby, N., Jorm, A.F., Creasey, H. and Broe, G.A. 1992, Cholinergic “blockade” as a model of the cognitive deficits in Alzheimer’s disease. Brain 115: 1681–1699.
Davies, P. and Maloney, A.J.R. 1976, Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii 1403.
Benton, J.S., Bowen, D.M., Allen, S.J., Haan, E A, Davison, A.N., Neary, D., Murphy, R.P. and Snowden, J.S. 1982, Alzheimer’s disease as a disorder of isodendritic care. Lancet ii 456.
McGeer, P.L., McGeer, E.G., Suzuki, J., Dolman, C.E. and Nagai, T. 1984, Aging, Alzheimer disease and the cholinergic system of the basal forebrain. Neurology 34: 741–745.
Palmer, A.M. and Dekosky, S.T. 1993, Monoamine neurons in aging and Alzheimer disease. J. Neural Transm. 91: 135–139.
Giacobini, E. 1991, Nicotinic cholinergic receptors in human brain: effects of aging and Alzheimer. Adv. Exp. Med. Biol. 296: 303–315.
De Keyser, J. 1992, Loss of high-affinity agonist receptor binding in Alzheimer’s disease. Ann. Neurol. 31: 231–232.
Greenamyre, J.T. and Maragos, W.G. 1993, Neurotransmitter receptors in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 5: 61–94.
Blin, J., Baron, J.C., Dubois, B., Crouzel, C., Fiorelli, M., Attar-Levy, D., Pillon, B., Fournier, D., Vidailhet, M. and Agid, Y. 1993, Loss of brain 5HT-2 receptors in Alzheimer’s disease. Brain 11: 497–510.
Joyce, J.N., Kaeger, C., Ryoo, H. and Goldsmith, S. 1993, Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer’s disease. Neurosci. Lett. 154: 171–174.
Frederickson, R. C. A. 1992, Astroglia in Alzheimer’s disease Neurobiol. Aging 13: 239–253.
McGeer, P.L., Kawamata, T., Walker, D.G., Akiyama, H., Tooyama, I. and McGeer, E.G. 1993, Microglia in degenerative and neurological disease. Canad. Sci. Neurol. 16: 511–515.
Hefti, F. and Schneider, L.S. 1991, Nerve growth factor in Alzheimer’s disease. Clin. Neuropharmacol. 14, Suppl. 1, S62–S76.
Vandenbeele, P. and Fiers, W. 1991, Is amyloidogenesis during Alzheimer’s disease due to IL-1/11–6 - mediated acute phase response in the brain? Immunol. Today 12: 217–219.
Markesbury, W.R., Ehmann, W.D., Hossain, T.I.M., Alauddin, M. and Goodin, D.T. 1981, Instrumental neutron activation analysis of brain aluminum in Alzheimer disease and aging. Ann. Neurol. 10: 511–516.
Thompson, C.M., Markesbery, W.R., Ehmann, W.D., Mao, Y.X. and Vance, D.E. 1988, Regional brain trace element studies in Alzheimer’s disease. Neurotoxicology 9: 1–8.
Deloncle, R. and Guillard, O. 1990, Mechanism of Alzheimer’s disease: Arguments for a neurotransmitter-aluminium complex implication. Neurochem. Res. 15: 1239–1245.
Good, P.F., Perl, D.P., Bierer, L.M. and Schmeidler, J. 1992, Selective accumulation ofaluminum and iron in the neurofibrillary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31: 286–292.
Evans, P.H., Klinowski, J., Yano, E. and Urano, N. 1989, Alzheimer’s disease: a pathogenetic role for aluminium silicate-induced phagocytic free radicals. Free Rad. Res. Commun. 6: 317–321.
Maragos, W.F., Greenamyre, T., Penney, Jr. J.B. and Young, A.B. 1987, Glutamate dysfunction in Alzheimer’s disease, an hypothesis. TINS 10: 65–68.
Lawlor, B.A. and Davis, K.L. 1992, Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer’s disease? Biol. Psychiatry 31: 337–350.
Hardy, J. and Allsop, D. 1991, Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. TIPS 12: 383–388.
Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G. and Cotman, C.W. 1993, Neurodegeneration induced by /3-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13: 1676–1687.
Gorenstein, C. 1987, A hypothesis concerning the role of endogenous colchicin-like factors in the etiology of Alzheimer’s disease. Med. Hypotheses 23: 371–374.
Seiler, N. 1993, Is ammonia a pathogenetic factor in Alzheimer’s disease? Neurochem. Res. 18: 235–245.
Prusiner, S.D. 1984, Some speculations about prions, amyloid and Alzheimer’s disease. N. Engl. J. Med. 310: 661–663.
Cooper, A.J.L. and Plum, F. (1987) Biochemistry and physiology of brain ammonia. Physiol. Rev. 67: 440–519.
Fisman, M., Ball, M. and Blume, W. 1989, Hyperammonemia and Alzheimer’s disease. J. Am. Ger. Soc. 37: 1102.
Fisman, M., Gordon, B., Felcki, V., Helmes, E., Appell, J. and Rabhern, K. 1985, Hyperammonemia in Alzheimer’s disease. Am. J. Psychiatry 142: 71–73.
Branconnier, R.J., Dessain, E.C., McNiff, M.E. and Cole, J.O. 1986, Blood ammonia and Alzheimer disease. Am. J. Psychiatry 143: 1313.
Hoyer, S., Nitsch, R. and Oesterreich, K. 1990, Ammonia is endogenously generated in the brain in the presence of presumed and verified dementia of Alzheimer type. Neurosci. Lett. 117: 358–368.
Butterworth, R.F., Giguere, J.F., Michaud, J., Lavoie, J. and Pomier-Layrargues, G. 1987, Ammonia: Key factor in the pathogenesis of hepatic encephalopathy. Neurochem. Pathol. 6: 1–12.
Zieve, L. 1987, Pathogenesis of hepatic encephalopathy. Metabolic Brain Dis. 2: 147–165.
Weil-Malherbe, H. and Drysdale, A.C. 1957, Ammonia formation in brain. III. Role of protein amide groups and of hexosamines. J. Neurochem. 1: 250–257.
Kvamme, E. 1983, Ammonia metabolism in the CNS. Progr. Neurobiol. 20: 109–132.
Faff-Michalak, L. and Albrecht, J. 1993, Hyperammonemia and hepatic encephalopathy stimulate rat cerebral synaptic mitochondrial glutamate dehydrogenase activity specifically in the direction of glutamate oxidation. Brain Res. 618: 299–302.
Smith, C.D., Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Stadtman, E.R., Floyd, R.A. and Markesbery, W.R. 1991, Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA 88: 10540–10543.
Le Prince, G., Delaere, P., Fages, C., Lefrancois, T., Touret, M. and Tardy, M. 1995, Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer Type. Neurochem. Res. 20: 859–862.
Procter, A.W., Palmer, A.M., Francis, T.D., Low, S.L., Neary, D., Murphey, E., Doshi, R. and Bowen,D.M. 1988, Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer’s disease. J. Neurochem. 50: 790–802.
Wallace, D R. and Dawson, Jr. R. 1992, Ammonia regulation of phosphate-activated glutaminase displays regional variation and impairment in the brain of aged rats. Neurochem. Res. 17: 1113–1122
Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Landeem, R.W., Cheng, M.S., Wu, J.F. and Floyd, R.A. 1991, Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert.butyl-a-phenylnitrone. Proc. Natl. Acad. Sci. USA 88: 3633–3636.
Oliver, C.N., Starke-Reed, P.E., Stadtman, E.R., Liu, G.J., Carney, J.M. and Floyd, R.A. 1990, Oxidative damage to brain proteins, loss of gutamine synthetase activity and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci. USA 87: 5144–5147.
Adolfsson, R., Gottfries, C.G., Oreland, L. and Winblad, B. 1980, Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27: 1029–1034.
Rainikainen, K.J., Paljärvi, L., Halonen, T., Malminen, O., Kosma, V.M., Laakso, M. and Riekkinen, P.J. 1988, Dopaminergic system and monoamine oxidase B activity in Alzheimer’s disease. Neurobiol. Aging 9: 245–252.
Nakamura, S., Kawamata, T., Akiguchi, I., Kamayama, M., Nakamura, N. and Kimura, H. 1990, Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 80: 419–425.
Mangoni, A., Grassi, M.P., Frattola, L., Piolti, R., Bassi, S., Motta, A., Marcone, A. and Smirne, C. 1991, Effect of an MAO B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 31: 100–107.
Li, X.M., Juorio, A.V. and Boulton, A.A. 1995, Some new mechanisms underlying the actions of (-)deprenyl: possible relevance to neurodegeneration. Progr. Brain Res. 106: 99–112.
Raabe, W.A. and Onstad, G.A. 1982, Ammonia and methionine sulfoximine intoxication. Brain Res. 242: 291–298.
Yamamoto, T., Iwasaki, K., Sato, Y., Yamamoto, H. and Konno, H. 1989, Astrocytic pathology of methionine sulfoximine-induced encephalopathy. Acta Neuropathol. 77, 357–368.
Jessy, J., Mans, A.M., De Joseph, R.M., and Hawkins, A. 1990, Hyperammonemia causes many of the changes found after portacaval shunting. Biochem. J. 272, 311–317.
Raabe, W.A. 1987, Synaptic transmission in ammonia intoxication. Neurochem. Pathol. 6: 145–166.
Lockwood, A.H., Yap, E.W.G. and Wong, W.H. 1991, Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J. Cerebral Blood Flow Metab. 11: 337–341.
McGeer, E.G., McGeer, P.L., Akiyama, H. and Harrop, R. 1989, Cortical glutaminase and glucose utilization in Alzheimer’s disease. J. Canad. Sci. Neurol. 16: 511–515.
Foster, N.L., Chase, T.N., Mansi, L., Brooks, R., Fedio, P., Patronas, N.J. and Dichiro, G. 1984, Cortical abnormalities in Alzheimer’s disease. Ann. Neurol. 16: 649–654.
Fukuyama, H., Harada, K., Yamauchi, H., Miyoshi, T., Yamagushi, S., Kimura, J., Kameyama, M., Senda, M., Yonekura, Y. and Konishi, J. 1991, Coronal reconstruction images of glucose metabolism in Alzheimer’s disease. J. Neurol. Sci. 106: 128–134.
Hoyer, S. 1991, Abnormalities of glucose metabolism in Alzheimer’s disease. Ann. N.Y. Acad. Sci. 640: 53–58.
Frackowiak, R.S., Possili, C., Legg, N.J., Du Boulay, G.H., Marshall, J., Lenzi, G.L. and Jones, T. 1981, Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104: 753–778.
Heiss, W.D., Szelies, B., Kessler, J. and Herholz, K. 1991, Abnormalities of energy me- tabolism in Alzheimer’s disease studied with PET. Ann. N.Y. Acad. Sci. 640: 65–71.
Parker, Jr. W.D., 1991, Cytochrome oxidase deficiency in Alzheimer’s disease. Ann. N.Y. Acad. Sci. USA 640: 59–64.
Liguri, G., Taddei, N.,Nassi, P., Matorraca, S., Nediani, C. and Sorbi, S. 1990, Changes in Na+,K+-ATPase, Ca2+-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer’s disease. Neurosci. Lett. 112: 338–342.
Gibson, G.E., Zimber, A., Krook, L., Richardson, E.P. and Visek, W.J. 1974, Brain his- tology and behavior of mice injected with urease. J. Neuropathol. Exp. Neurol. 33: 201–211.
Martin, H., Voss, K., Hufnagl, P., Wack, R. and Wassilew, G. 1987, Morphometric and densitometric investigations of protoplasmic astrocytes and neurons in hepatic encephalopathy. Exp. Pathol. 32: 198–237.
Butterworth, R.F., Girard, G. and Giguère, J.F. 1988, Regional differences in the capacity for ammonia removal by brain following portacaval anastomosis. J. Neurochem. 51: 486–490.
Swain, M.S., Blei, A.T., Butterwortth, R.F. and Kraig, R.P. 1991, Intracellular pH rises and astrocytes swell after portacaval anastomosis in rats. Am; J. Physiol. 261 R1491–R1496.
Pomara, N., Singh, R., Deptula, D., Chou, J.C.Y., Banay-Schwartz, M. and Le Witt, P.A. (1992) Glutamate and other CSF amino acids in Alzheimer’s disease. Am. J. Psychiatry 149: 251–254.
Therrien, G. and Butterworth, R.F. 1991, Cerebrospinal amino acids in relation to neurological status in experimental portal-systemic encephalopathy. Metabolic Brain Dis. 6: 65–74.
Tossman, U., Delin, A., Eriksson, L.S. and Ungerstedt, U. 1987, Brain cortical amino acids measured by intracerebral dialysis in portacaval shunted rats. Neurochem. Res. 12: 265–269.
Benowitz, L.I., Rodriguez, W., Paskevich, P., Mufson, E.J., Schenk, D. and Neve, R.L. 1989, The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects. Exp. Neurol. 106: 237–250.
Cole, G.M., Huynh, T.V. and Saitoh, T. 1989, Evidence for lysosomal processing of amyloid beta-protein precursor in cultured cells. Neurochem. Res. 14: 933–939.
Kawai, M., Cras, P., Richey, P., Tabaton, M., Lowery, D.E., Gonzalez-DeWitt, P.A., Greenberg, B.G., Gambetty, P. and Perry, G. 1992, Subcellular localization of amyloid precursor protein in senile plaques of Alzheimer’s disease. Am. J. Pathol. 140; 947–958.
Cataldo, A.M., Thayer, C.Y., Bird, E.D., Wheelock, T.R. and Nixon, R.A. 1990, Lysosomal proteinase antigens are prominently localized within senile plaues of Alzheimer’s disease: evidence for a neuronal origin. Brain Res. 513: 181–192.
Caporaso, G.L., Gandy, S.E., Buxbaum, J.D. and Greengard, P. 1992, Chloroquine inhibits intracellular degradation but not secretion of Alzheimer â—A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA 89: 2252–2256.
Golde, T.E., Estus, S., Younkin, L.H., Selkoe, D.J. and Younkin, S.G. 1992, Processing of the amyloid precursor protein to potentially amyloidogenic derivatives. Science 255: 728–730.
Segelen, P.O. 1983, Inhibitors of lysosomal function. Meth. Enzymol. 96: 737–765.
Glimelius, B., Westermark, B. and Wasteson, A. 1977, Ammonium ion interferes with the lysosomal degradation of glycosaminoglycans in cultures of human glial cells. Exp. Cell Res. 107: 201–217.
Felipo, V., Minana, M.D., Wallacer, R. and Grisolia, S. 1988, Long-term ingestion of ammonium inhibits lysosomal proteolysis in rat liver. FEBS Lett. 234: 213–214.
Dickson, D.W., Farlo, J., Davies, P., Crystal, H., Fuld, P. and Yen, S.H. 1988, Alzhei- mer’s disease: a double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132: 86–101.
Felipo, V., Grau, E., Minana, M.D. and Grisolia, S. 1993, Ammonium injection induces N-methyl-D-aspartate receptor - mediated proteolysis of the microtubuleassociated protein MAP-2. J. Neurochem. 60: 1626–1630.
Tsuboi, M., Harasawa, K., Izawa, T., Komabayashi, T., Fujinami, H. and Suda, K. 1993, Intralysosomal pH and release of lysosomal enzymes in the rat liver after exhaustive exercise. J. Appl. Physiol. 74: 1628–1634.
Leoni, P. and Dean, R.T. 1983, Mechanism of lysosomal enzyme secretion by human monocytes. Biochim. Biophys. Acta 762: 378–389.
Cataldo, A.M. and Nixon, R.A. 1990, Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. USA 87: 3861–3865.
Cataldo, A.M., Paskevich, P.E., Kominami, E. and Nixon, R.A. 1991, Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 88: 10998–11002.
Nakamura, Y, Takeda, M., Suzuki, H., Hattori, H., Tada, K., Hariguchi, S., Hashimoto, S. and Nishimura, T. 1991, Abnormal distribution of cathepsins in the brain of patients with Alzheimer’s disease. Neurosci. Lett. 130: 195–198.
Atanassov, C.L., Muller, C.D., Sarhan, S., Knödgen, B., Rebel, G. and Seiler, N. 1994, Effect of ammonia on endocytosis, cytokine production and lysosomal enzyme activity of a microglial cell line. Res. Immunol. 145: 277–288.
Atanassov, C.L., Muller, C.D., Dumont, S., Rebel, G., Poindron, P. and Seiler, N. 1995, Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells. Neurochem Int. 27: 417–424.
Mukaida, N., Harada, A., Yasumoto, K. and Matsushima, K. 1992, Properties of pro-inflammatory cell type-specific leukocyte chemotactic cyokines, interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF). Microbiol. Immunol. 36: 773–789.
Berkenbosch, F., Biewenga, J., Brouns, M., Rozemuller, J.M., Strijbos, P. and Van Dam, A.M. 1992, Cytokines and inflammatory proteins in Alzheimer’s disease. Res. Immunol. 143: 657–663.
McGeer, P.L. and Rogers, J. 1992, Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 42: 447–448.
Curzon, G., Kantamaneni, B.D., Winch, J., Rochas-Bueno, A., Murray-Lyon, LM. and Williams, R. 1973, Plasma and brain tryptophan changes in experimental acute hepatic failure. J. Neurochem. 21: 137–145.
Record, C.O. 1991, Neurochemistry of hepatic encephalopathy. Gut 32: 1261–1263.
Bachmann, C. and Colombo, J.P. 1983, Increased tryptophan uptake into the brain in hyperammonemia. Life Sci. 33: 2417–2424.
Foster, A.C. and Schwarcz, R. 1989, Neurotoxic effects of quinolinic acid in the mammalian central nervous system. In Quinolinic Acid and Kynurenines (Stone, W. Ed.) CRC Press, Boca Raton, pp 173–192.
Kornhüber, J., Wichart, I., Riederer, P., Kleinberger, G. and Jellinger, K. 1989, Kynurenine in hepatic encephalopathy. In Quinolinic acid and Kynurenines (Stone, T.W. Ed.) CRC Press, Boca Raton, pp 275–281.
Moroni, F., Lombardi, G. and Carla, V. 1989, The measurement of quinolinic acid in the mammalian brain: Neuropharmacological and physiopathological studies. In Quinolinic Acid and Kynurenines (Stone, T.W. Ed.) CRC Press, Boca Raton, pp 53–62.
Grinde, B. 1989, Kynurenine and lysosomal proteolysis. In Quinolinic Acid and Kynurenines (Stone, T.W. Ed.) CRC Press, Boca Raton, pp 91–97.
Uribe, M. 1989, Nutrition, diet and hepatic encephalopathy. In Hepatic Encephalopathy: Pathophysiology and Treatment (Butterworth, R.F. and Pomier Layrargues, Eds.) Humana Press, Clifton, pp. 529–547.
Seiler, N. 1997, Ornithine aminotransferase as a therapeutic target in hyperammonemias. This volume.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Plenum Press, New York
About this chapter
Cite this chapter
Seiler, N. (1997). An Ammonia Hypothesis of Alzheimer Disease. In: Felipo, V., Grisolía, S. (eds) Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology, vol 420. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5945-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5945-0_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-45598-8
Online ISBN: 978-1-4615-5945-0
eBook Packages: Springer Book Archive